Gavi, the Vaccine Alliance, a public–private global health partnership with the goal of increasing access to immunisation in developing countries, is celebrating after working with lower-income countries to reach a key target to vaccinate millions of girls with the human papillomavirus (HPV) vaccine for cervical cancer in mid-November, 2025—6 weeks ahead of its original 3-year target.
[News] Gavi hits HPV vaccine milestone early but concerns surround future funding
The Lancet Oncology | | Tony Kirby
Topics: blood-cancer, cervical-cancer, prevention